Albunorm 20% solution for infusions 50 ml. №1 vial

Albunorm (Albumin) 20% solution for infusions 50 ml. №1 vial

$159.00

Manufacturer: Germany

Albunorm (Albumin) is used for restoration and maintenance of circulating blood volume in a volume deficit, if the use of a colloid is indicated.

Category:

Description

Composition

active ingredient: human albumin;

1000 ml solution for infusion contains 200 g of plasma proteins with a human albumin content of at least 96%;

excipients: sodium, N-acetyl-DL-tryptophan, caprylic acid, water for injection.

Dosage form

Solution for infusion.

Basic physical and chemical properties: transparent, slightly viscous liquid, almost colorless, yellow, amber or green.

Pharmacotherapeutic group

Сlose related drugs. Blood substitutes and plasma protein fractions. ATX code B05A A01.

Pharmacodynamics

Human albumin accounts for more than half of the total protein in blood plasma and corresponds to approximately 10% of the activity of liver protein synthesis.

Human albumin 200 g/l has a corresponding hyperoncotic effect.

The most important physiological function of albumin is to maintain blood oncotic pressure and transport function. Albumin stabilizes circulating blood volume and transports hormones, enzymes, drugs, and toxins.

Indications

Restoration and maintenance of circulating blood volume in a volume deficit, if the use of a colloid is indicated.

The choice of albumin over a synthetic colloid should be based on official recommendations depending on the clinical condition of the individual patient.

Contraindications

Hypersensitivity to protein blood products or to any of the excipients.

Application features

The composition of the medicinal product includes potassium, which is a component of human blood plasma and is not added specifically as an excipient.

Suspicion of an allergic or anaphylactic reaction requires immediate discontinuation of the drug. In case of shock, standard medical treatment for shock should be performed.

The solution should be used with caution when there is a particular risk of hypervolemia and its consequences or hemodilution for the patient, for example in the case of:

  • decompensated heart failure;
  • hypertension;
  • varicose esophagus;
  • pulmonary edema;
  • hemorrhagic diathesis;
  • severe anemia;
  • renal or postrenal anuria.

In critically ill patients with traumatic brain injury, rehydration with albumin is associated with a higher risk of mortality than rehydration with saline. Caution is advised when using albumin in patients with severe traumatic brain injury.

The colloid osmotic effect of human albumin 200 or 250 g/l is approximately 4 times higher than the colloid osmotic effect of blood plasma. Therefore, when administering concentrated albumin, care must be taken to ensure proper hydration (replenishment of fluid loss) of the patient. Patients should be closely monitored to prevent circulatory overload and overhydration.

Solutions of human albumin 200-250 g/l have a relatively low content of electrolytes compared to solutions of human albumin 40-50 g/l. When using albumin, the patient’s electrolyte status should be monitored and appropriate measures taken to restore or maintain electrolyte balance.

The solutions must not be diluted with water for injection as this may cause hemolysis in patients.

If large volumes are administered, the drug should be warmed to room temperature or body temperature before use.

Do not use solutions that are cloudy or have a precipitate. This may indicate that the protein is unstable or that the solution has become contaminated.

Once the vial has been opened, its contents should be used immediately.

Related products